A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov
SY Wang, WQ Liu, YQ Li, JX Li… - Expert Review of Vaccines, 2023 - Taylor & Francis
Introduction The global spread of COVID-19 has prompted the development of vaccines. A
recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by …
recombinant adenovirus type-5 vectored COVID-19 vaccine (Ad5-nCoV) developed by …
Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
KA Pasquevich, LM Coria, A Ceballos… - Nature …, 2023 - nature.com
Abstract A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called
ARVAC CG was selected for a first in human clinical trial. Healthy male and female …
ARVAC CG was selected for a first in human clinical trial. Healthy male and female …
[HTML][HTML] Construction and application of adenoviral vectors
H Zhang, H Wang, Y An, Z Chen - Molecular Therapy. Nucleic …, 2023 - ncbi.nlm.nih.gov
Adenoviral vectors have been widely used as vaccine candidates or potential vaccine
candidates against infectious diseases due to the convenience of genome manipulation …
candidates against infectious diseases due to the convenience of genome manipulation …
High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity
NG Nuñez, J Schmid, L Power, C Alberti… - Nature …, 2023 - nature.com
The range of vaccines developed against severe acute respiratory syndrome coronavirus 2
(SARS‑CoV‑2) provides a unique opportunity to study immunization across different …
(SARS‑CoV‑2) provides a unique opportunity to study immunization across different …
Comparison of immunogenicity and reactogenicity of five primary series of COVID-19 vaccine regimens against circulating SARS-CoV-2 variants of concern among …
T Sudjaritruk, O Mueangmo, J Saheng, P Winichakoon… - Vaccines, 2023 - mdpi.com
To compare immunogenicity and reactogenicity of five COVID-19 vaccine regimens against
wild-type SARS-CoV-2 and variants of concern (VoCs) among Thai populations, a …
wild-type SARS-CoV-2 and variants of concern (VoCs) among Thai populations, a …
Soluble SARS‐CoV‐2 RBD and human ACE2 peptidase domain produced in Drosophila S2 cells show functions evoking virus–cell interface
F Carrión, F Rammauro, N Olivero‐Deibe… - Protein …, 2023 - Wiley Online Library
The interaction between the receptor‐binding domain (RBD) of the spike glycoprotein of
SARS‐CoV‐2 and the peptidase domain of the human angiotensin‐converting enzyme 2 …
SARS‐CoV‐2 and the peptidase domain of the human angiotensin‐converting enzyme 2 …
Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina
PE Rodriguez, AP Silva, EA Miglietta, P Rall… - Frontiers in …, 2022 - frontiersin.org
The COVID-19 pandemic has particularly affected older adults residing in nursing homes,
resulting in high rates of hospitalisation and death. Here, we evaluated the longitudinal …
resulting in high rates of hospitalisation and death. Here, we evaluated the longitudinal …
[HTML][HTML] Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals
H Sharif, H Ghani, L Ahmad, S Bagol, J Wong, CW Tan… - Vaccine, 2023 - Elsevier
BBIBP-CorV inactivated vaccine is one of the most prevalent vaccines globally, but immune
responses are far less studied than novel COVID-19 vaccine platforms. Longitudinal studies …
responses are far less studied than novel COVID-19 vaccine platforms. Longitudinal studies …
Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine
É Rákóczi, G Magócs, S Kovács, B Nagy Jr, G Szűcs… - Diagnostics, 2023 - mdpi.com
Objectives: In this prospective study, SARS-CoV− 2 spike protein specific total
immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster …
immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster …
Immunogenicity and durability of antibody responses to homologous and heterologous vaccinations with BNT162b2 and chAdOx1 vaccines for COVID-19
DI Kim, SJ Lee, S Park, P Kim, SM Lee, N Lee, D Shum… - Vaccines, 2022 - mdpi.com
During the COVID-19 pandemic, vaccines were developed based on various platform
technologies and were approved for emergency use. However, the comparative analysis of …
technologies and were approved for emergency use. However, the comparative analysis of …